Clover Health Investments Corp. Class A (CLOV)
NASDAQ: CLOVHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLOV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.00B
- P/E (TTM)
- 373.00
- Forward P/E
- 20.72
- EPS (TTM)
- $0.01
- Dividend yield
- None
- 52-week range
- 1.58 – 5.59
- Day range
- 3.68 – 3.96
- Volume / Avg
- 7.24M / 4.49M
- Beta
- —
- Shares outstanding
- 439.71M
52-week range
CLOV stock today
On Nov 20, CLOV ended the session at $3.73, shedding $0.04 (1.06%), versus the S&P 500's 3.70% decline. At this level, CLOV sits in the middle of its 52-week range of $1.58 to $5.59: 33.3% below the high, set on Jun 29, 2026 and 136.1% above the low. CLOV is up 58.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 63.6%.
At 373.0x trailing earnings, Clover Health Investments trades above the peer-group median of 45.5x. Its forward P/E of 20.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Clover Health Investments
Company profileClover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Andrew Toy
- Headquarters
- Wilmington, DE
- Employees
- 724
- Website
- cloverhealth.com
Financial highlights
Full financialsIn fiscal 2025, Clover Health Investments generated $1.92 billion in revenue, up 40.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Clover Health Investments reported a net loss of $85.5 million, compared with a loss of $43.0 million a year earlier. Operating margin was -4.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.92B | $1.37B | $1.26B | $1.10B | $1.47B |
| Growth | +40.34% | +8.77% | +14.96% | -25.51% | +118.76% |
| Net income | $-85.55M | $-43.01M | $-213.36M | $-339.57M | $-587.76M |
| EPS (diluted) | $-0.17 | $-0.09 | $-0.44 | $-0.71 | $-1.42 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$5.60+50.13%
- Strong buy 1
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.05 vs $-0.01
- Surprise
- -400.00%
CLOV news
All CLOV news- Notable Wednesday Option Activity: BHF, CLOV, GSNasdaqBHF, CLOV, GS
- Notable Tuesday Option Activity: HROW, CLOV, RCATNasdaqHROW, CLOV, RCAT
- Noteworthy Monday Option Activity: ALRS, CLOV, BANasdaqALRS, CLOV, BA
- Needham Initiates Coverage of Clover Health Investments at BuyNasdaqCLOV, SUN
- Clover Health to Participate in Upcoming UBS Global Healthcare ConferenceGlobeNewswire
- Notable Tuesday Option Activity: BETR, SMCI, CLOVNasdaqBETR, SMCI, CLOV
- Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three StatesGlobeNewswire
- Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027GlobeNewswire
Clover Health Investments peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VCYTVeracyte Inc. | 25.13 | +0.36% | $2.03B | vs CLOV |
| FTREFortrea Holdings Inc. | 18.55 | -7.94% | $1.79B | vs CLOV |
| PSNLPersonalis Inc. | 14.27 | -3.06% | $1.55B | vs CLOV |
| TRUPTrupanion Inc. | 35.56 | -0.86% | $1.54B | vs CLOV |
| CELCCelcuity Inc. | 53.35 | -5.26% | $2.61B | vs CLOV |
| LMRILumexa Imaging Holdings Inc. | 14.26 | +1.42% | $1.37B | vs CLOV |
| ALHCAlignment Healthcare Inc. | 6.37 | -2.00% | $1.33B | vs CLOV |
| FRNMFreenome Inc. | 9.36 | -5.69% | $1.04B | vs CLOV |
Indexes, lists and sector
Clover Health Investments stock FAQ
What is Clover Health Investments's stock price today?
CLOV last traded at $3.73 as of Nov 20, 4:00 PM EST, down 1.06% on the day. Prices are delayed at least 15 minutes.
What is CLOV's P/E ratio?
CLOV trades at a trailing P/E ratio of 373.00 and a forward P/E of 20.72, compared with a median of 45.5 for its closest peers.
Who is Clover Health Investments's CEO?
Mr. Andrew Toy is the chief executive officer of Clover Health Investments Corp. Class A, which has about 724 employees.
What is the CLOV 52-week high?
The 52-week high for CLOV is $5.59 and the 52-week low is $1.58. The stock is currently 33.3% below its high.